Understanding the Pharvaris Portfolio at ACAAI 2025
The recent ACAAI Annual Scientific Meeting showcased significant findings regarding the Pharvaris portfolio, particularly focusing on deucrictibant. The oral presentations highlighted data that support the long-term safety profile and sustained benefits of deucrictibant, demonstrating its potential impact on the treatment of hereditary angioedema (HAE).
Key Data Presented at ACAAI 2025
Among the critical insights presented, data from the CHAPTER-1 study significantly underscored deucrictibant’s compatibility for up to approximately 34 months, with an impressive average of 92.4% reduction in HAE attacks from the study baseline. These results were derived from the open-label portion of the study, confirming the drug's well-tolerated safety profile.
Moreover, six additional posters offered further evidence regarding the safety, effectiveness, and health-related quality of life outcomes from various clinical studies that reaffirm deucrictibant's promising distinctiveness in managing HAE.
Statements from Pharvaris Leadership
Berndt Modig, Chief Executive Officer of Pharvaris, expressed pride in the acknowledgment from the scientific community regarding the late-stage confirmatory data of deucrictibant. He conveyed optimism about how this treatment could potentially enhance the quality of life for individuals grappling with bradykinin-mediated angioedema.
Long-Term Safety and Efficacy Analysis
The primary focus during the presentations was the analysis of the long-term prophylactic potential of oral deucrictibant. Dr. Marc A. Riedl shared insights from the open-label extension of the Phase 2 clinical study, underlining that participants showed sustained low attack rates, maintaining a mean of only 0.12 attacks per month while on treatment.
Dr. Peng Lu, Chief Medical Officer of Pharvaris, reinforced the positive clinical outcomes achieved thus far with deucrictibant and expressed anticipation for the Phase 3 data readout of the CHAPTER-3 trial, set to take place in the upcoming timeframe.
Enhancing Quality of Life
A significant component of the discussion revolved around how continuous treatment with deucrictibant contributes to better control of HAE and overall health-related quality of life (HRQoL). Findings from Dr. Michael E. Manning’s presentation illustrated that treatment improved not only clinical outcomes but also the everyday lives of individuals affected by HAE.
Investigating On-Demand Treatment
Data on on-demand treatments were demonstrated through the findings presented by Dr. Joshua S. Jacobs. He discussed the durability of response achieved following a single dose of deucrictibant's immediate-release capsule, where a significant percentage of patients experienced symptom resolution swiftly.
Future Outlook for Deucrictibant
Pharvaris continues its commitment to addressing unmet needs in bradykinin-mediated diseases. With ongoing studies, the company aims to offer innovative solutions that provide both efficacy and tolerability in oral forms. As Pharvaris moves forward, they remain dedicated to delivering impactful therapies that could transform the lives of those affected by HAE.
Clinical validation of a kinin biomarker assay was also a notable point presented, which may play a significant role in characterizing patients with bradykinin-mediated angioedema, further enhancing treatment precision and effectiveness.
Frequently Asked Questions
What is deucrictibant?
Deucrictibant is a novel oral medication in development for the treatment and preventive care of hereditary angioedema, targeting bradykinin signaling pathways.
What were the key findings from the ACAAI 2025 on deucrictibant?
The main findings included a well-tolerated safety profile and significant reduction in HAE attack rates over long-term treatment periods, highlighting its efficacy and benefits.
How does deucrictibant improve quality of life?
Studies show that deucrictibant enhances disease control and significantly improves health-related quality of life outcomes for patients suffering from HAE.
What future studies is Pharvaris conducting?
Pharvaris is advancing into Phase 3 studies to further assess the efficacy and safety of deucrictibant for both prophylactic and on-demand treatment of HAE attacks.
How can I learn more about Pharvaris and its products?
For further details, visit the official Pharvaris website or their Investor section, where updates and data presentations are shared.
